Cytokine

Myeloid Therapeutics to Showcase In Vivo CAR Data and its Diverse mRNA Platform at AACR

Retrieved on: 
Thursday, April 4, 2024
Vivo, Canadian Aviation Regulations, Patient, Primate, RNA, Fragment crystallizable region, Cancer, Messenger, AACR, Chemokine, Cytokine, Drug development, Safety, Myeloid tissue, NK, LNP, Antigen, Annual general meeting, Vaccine

This advancing study represents the first human trial of any in vivo chimeric antigen receptor (CAR) therapy.

Key Points: 
  • This advancing study represents the first human trial of any in vivo chimeric antigen receptor (CAR) therapy.
  • Myeloid will also share information on its portfolio of immune cell programming CARs.
  • "We are thrilled to continue driving this first in vivo mRNA CAR program forward," said Chief Executive Officer Daniel Getts, Ph.D. "Myeloid is at the forefront of in vivo immune cell programming.
  • To date, Myeloid has demonstrated CAR activity in human cells, and following systemic mRNA/LNP delivery in mouse and non-human primates.

RemeGen's Telitacicept (RC18) Granted Fast Track Designation by United States FDA for Treatment of Primary Sjögren's Syndrome

Retrieved on: 
Wednesday, April 3, 2024
Rheumatoid arthritis, Autoimmunity, Lupus, Risk, Rheumatism, Patient, PSS, SLE, Diabetic nephropathy, Myasthenia gravis, IND, Mouth, Investigational New Drug, Cytokine, B-cell activating factor, Iga, FDA, FTD

The FDA grants FTD to accelerate the development and review of new drugs that have the potential to treat life-threatening conditions and address unmet medical needs.

Key Points: 
  • The FDA grants FTD to accelerate the development and review of new drugs that have the potential to treat life-threatening conditions and address unmet medical needs.
  • Telitacicept prevents abnormal differentiation and maturation of B-cells through a two-pronged approach, thereby treating various autoimmune diseases mediated by B-cells.
  • In December 2023, Telitacicept was granted Investigational New Drug (IND) by the FDA for the treatment of active pSS in adults.
  • Dr. Jianmin Fang, CEO of RemeGen, commented, "As the first fusion protein drug of its kind independently developed by RemeGen, we are delighted the FDA has recognized Telitacicept for fast track designation.

Advancing CAR T-Cell Therapies with Clinical Trial Customization, Upcoming Webinar Hosted by Xtalks

Retrieved on: 
Monday, March 25, 2024
ChromeOS, Genomics, Gene, Flow cytometry, Biomarker, Doctor of Philosophy, Clinical trial, Cytokine, CGT, Patient safety, Therapy, Cell, Pharmaceutical industry

TORONTO, March 25, 2024 /PRNewswire-PRWeb/ -- Bringing together best practices in genomics, flow cytometry, biomarkers and clinical trial operations.

Key Points: 
  • In this free webinar, learn how to successfully set up and manage highly customized CAR T-cell therapy clinical trials.
  • Introducing new CAR T-cell therapies to the market requires extensive strategizing and planning for clinical trials as well as post-marketing follow-up.
  • This webinar emphasizes the challenges encountered and the importance of customized solutions in genomics, flow cytometry, biomarkers and clinical trial operations for successful CAR T-cell therapy clinical trials.
  • Register for this webinar today to learn more about customized solutions for successful CAR T-cell therapy clinical trials.

Verb Biotics Announces Data from Preclinical Studies to Support Foundational Gut Microbiome Health from Newly Launched Keystone Postbiotic™

Retrieved on: 
Tuesday, March 19, 2024
Health, Antioxidant, Keystone, Powder, Capsule, Probiotic, Butyric acid, Functional food, Overalls, Cytokine, MOA, Drink, Water, Prebiotic (nutrition), Immune system, Caco-2, Vaccine

BOSTON, March 19, 2024 /PRNewswire/ -- Verb Biotics, a microbiome health ingredient company, today announced preliminary preclinical data from their newly launched Keystone Postbiotic™, a foundational gut microbiome solution to help support and strengthen gut microbiome health.

Key Points: 
  • BOSTON, March 19, 2024 /PRNewswire/ -- Verb Biotics, a microbiome health ingredient company, today announced preliminary preclinical data from their newly launched Keystone Postbiotic™, a foundational gut microbiome solution to help support and strengthen gut microbiome health.
  • Verb Biotics has conducted thorough in-vitro and preliminary human studies to understand how Keystone Postbiotics' deliberately chosen active components contribute to maintaining a robust gut microbiome and a well-regulated immune response.
  • The preclinical data contributed to the decision by Verb Biotics to commence human clinical studies in January 2024 to evaluate the potential support of foundational gut microbiome health by Keystone Postbiotic™.
  • Keystone Postbiotic™ combines strains, grains, and botanicals to deliver functional redundancy to support foundational gut microbiome health.

Labroots Announces its 8th Annual Laboratory Automation Virtual Event, Scheduled on March 20, 2024

Retrieved on: 
Thursday, March 14, 2024
Automaton, Automation, Receptor, Almost, Q&A, Cell, Protein, Laboratory automation, MIT, LIMS, Sartorius, CDS, Research, Science News, WEI, Media lab, Science, Doctor of Philosophy, Networking hardware, Laboratory, Cytokine, CRISPR, Immortalised cell line, Labroots, Molecular biology, Medicine, UCLA, Antigen

YORBA LINDA, Calif., March 14, 2024 /PRNewswire-PRWeb/ -- Labroots, the leading scientific social networking website, offering premier, interactive virtual events and webinars, is delighted to host its 8th annual Laboratory Automation online event on March 20, 2024. This free event brings together thousands of research scholars, scientists, and laboratory personnel from leading academic and industry institutions under a virtual roof to explore scientific disciplines with sessions spanning microfluidic and microscale technologies for automation, automation and emerging methods, lab automation with cutting-edge tools, LIMS and other automation software, and analytics for high-throughput and high content assays.

Key Points: 
  • YORBA LINDA, Calif., March 14, 2024 /PRNewswire-PRWeb/ -- Labroots , the leading scientific social networking website, offering premier, interactive virtual events and webinars, is delighted to host its 8th annual Laboratory Automation online event on March 20, 2024.
  • The insightful agenda encompasses leading-edge advancements aimed at automating and accelerating research, and amplifying efficiency in the lab.
  • A lively Q&A session, following the presentation sponsored by Automata titled, "How to Prepare for Lab Automation."
  • Participants can use the official hashtag #LRlabauto to follow the conversation and connect with other members in the Laboratory Automation community!

Key protein linked to immune disorders

Retrieved on: 
Thursday, March 14, 2024
Health, B cell, Cell, Communication, Multiple sclerosis, Inflammation, Journal, Research, DSM-IV codes, Bacteria, Virus, Hokkaido University, Protein, Asthma, Cytokine, Infection, Immune system, Journal of Immunology, Antigen, Vaccine

SAPPORO, Japan, March 14, 2024 /PRNewswire/ -- A new study has shed light on the importance of the protein STAP-1 in activating certain immune cells. Understanding the role of STAP-1 in these cells could give researchers a better glimpse into immune-related disorders and ways to treat them.

Key Points: 
  • SAPPORO, Japan, March 14, 2024 /PRNewswire/ -- A new study has shed light on the importance of the protein STAP-1 in activating certain immune cells.
  • Understanding the role of STAP-1 in these cells could give researchers a better glimpse into immune-related disorders and ways to treat them.
  • "Our findings provide valuable insights into the molecular mechanisms underlying T cell activation and the development of immune disorders," says Tadashi Matsuda, a Hokkaido University professor who led the study.
  • Future research can build on this work by exploring the potential of STAP-1 as a therapeutic target for treating immune-related disorders.

Key protein linked to immune disorders

Retrieved on: 
Thursday, March 14, 2024
Health, B cell, Cell, Communication, Multiple sclerosis, Inflammation, Journal, Research, DSM-IV codes, Bacteria, Virus, Hokkaido University, Protein, Asthma, Cytokine, Infection, Immune system, Journal of Immunology, Antigen, Vaccine

SAPPORO, Japan, March 14, 2024 /PRNewswire/ -- A new study has shed light on the importance of the protein STAP-1 in activating certain immune cells. Understanding the role of STAP-1 in these cells could give researchers a better glimpse into immune-related disorders and ways to treat them.

Key Points: 
  • SAPPORO, Japan, March 14, 2024 /PRNewswire/ -- A new study has shed light on the importance of the protein STAP-1 in activating certain immune cells.
  • Understanding the role of STAP-1 in these cells could give researchers a better glimpse into immune-related disorders and ways to treat them.
  • "Our findings provide valuable insights into the molecular mechanisms underlying T cell activation and the development of immune disorders," says Tadashi Matsuda, a Hokkaido University professor who led the study.
  • Future research can build on this work by exploring the potential of STAP-1 as a therapeutic target for treating immune-related disorders.

CytomX Therapeutics Reports 2023 Financial Results and Provides Business Update

Retrieved on: 
Monday, March 11, 2024
Therapy, EDT, Head, CD3, SAN, Investigational New Drug, Cancer, EGFR, Research, Biotechnology, Partnering, TCE, Epithelial cell adhesion molecule, Investment, Melanoma, FDA, Amgen, Therapeutic index, Food, Camptothecin, Gastrointestinal tract, Bladder cancer, Drug discovery, CRC, ADC, Bristol Myers Squibb, BMS, Safety, Kidney, Cytokine, Webcast, Tumor microenvironment, PDT, Patient, Workforce, IND, Trial of the century, Colorectal cancer, Pharmaceutical industry

SOUTH SAN FRANCISCO, Calif., March 11, 2024 (GLOBE NEWSWIRE) -- CytomX Therapeutics, Inc. (Nasdaq: CTMX), a leader in the field of conditionally activated, localized biologics, today reported full year 2023 financial results and provided a business update.

Key Points: 
  • Throughout 2023, CytomX made substantial progress across all research partnerships including the commencement of programs under its new alliances with Regeneron and Moderna.
  • In 2023, CytomX remained focused on controlling costs and efficiently allocating capital towards its lead pipeline programs.
  • General and administrative expenses in the fourth quarter of 2023 were $7.8 million compared to $10.1 million in the corresponding period in 2022.
  • CytomX management will host a conference call and simultaneous webcast today at 5 p.m. EDT (2 p.m. PDT) to discuss the financial results and provide a business update.

ASLAN Pharmaceuticals Provides TREK-DX Study Update and Highlights Potential of Eblasakimab in Dupilumab-Experienced Atopic Dermatitis Patients

Retrieved on: 
Monday, March 11, 2024
Allergy, SAN, Conjunctivitis, Inflammation, EASI, Skin, Data, Cytokine, IGA, Patient, Disease, Dupilumab, ASLN, Pharmaceutical industry

In conjunction with this, independent reviewer confirmation of baseline EASI scores has also been implemented.

Key Points: 
  • In conjunction with this, independent reviewer confirmation of baseline EASI scores has also been implemented.
  • Of the 9 patients who previously had an inadequate response to dupilumab, 5 patients (56%) achieved EASI-90 and 5 patients (56%) a vIGA score of 0 or 1.
  • Additional data from head-to-head studies between eblasakimab and dupilumab in skin biopsies from AD patients confirmed the differentiated effects of targeting IL-13R versus IL-4R5.
  • In this study, eblasakimab reduced localized secretion of pro-inflammatory Type 2 cytokines by the skin tissue more efficiently than dupilumab, suggesting eblasakimab could have the potential to be effective in AD patients that do not achieve an adequate response to dupilumab.

Ludwig Enterprises Inc. (OTC:LUDG) Announces Patent Filing for Breakthrough in Identifying mRNA Genes Associated with Certain Cancers

Retrieved on: 
Wednesday, March 6, 2024
Breast cancer, Neoplasm, Messenger, Epigenome, OTC, Cancer, Bladder cancer, Stem cell, IRB, Breast, Biomarker, Element, Cytokine, Patent, Patient, Gene, Medicine, Thermo Fisher Scientific, Disease, Diagnosis, Machine learning, Trial of the century, Colorectal cancer, DNA, Environment, Vaccine

The Company’s mRNA for Life™ is a one-of-the-kind noninvasive at-home sceening test for genes that could be associated with cancer.

Key Points: 
  • The Company’s mRNA for Life™ is a one-of-the-kind noninvasive at-home sceening test for genes that could be associated with cancer.
  • This test allows a person to make themselves a priority and could be a signal to seek a medical examination.
  • The Company selected for measurement 48 distinct mRNA genes in stored specimens from patients afflicted with breast, bladder or colorectal cancer.
  • mRNA levels were analyzed using machine learning artificial intelligence (AI) to identify markers of genetic expression involved in separate cancers.